Mounjaro and Zepbound both contain tirzepatide, and both are given as an injection once a week. Official labelling for each names the same active ingredient. What differs is what each product is licensed to treat, and which of the two names you are likely to encounter where you live.

The practical effect is a specific kind of confusion. A reader taking one of them finds an article, a forum thread, or a news report about the other, cannot tell whether it describes their own medicine, and ends up either dismissing information that was relevant or absorbing information that was not.

The licensing difference, stated carefully

Zepbound was approved by the US regulator for chronic weight management, and its prescribing information is published as its own product document. Mounjaro is licensed for type 2 diabetes, and in some markets for weight management as well. NICE has separately assessed tirzepatide for managing overweight and obesity, which is an assessment of the ingredient inside a defined care pathway rather than a statement about brand names.

Regulatory positions move. A licence extended this year did not exist last year, and a page written now can describe a picture that has shifted by the time you read it. That is why the durable fact worth carrying is the one that does not move: both names are tirzepatide, and your own packaging and prescription are the authority on which product you personally have.

Why you may only ever see one name

Across much of Europe, tirzepatide is generally sold under the Mounjaro name for its licensed uses, and the Zepbound name is not commonly marketed there. A reader in Germany, France, or the UK who has been following American coverage will encounter the second name constantly and may never see it on a box in a local pharmacy.

That is worth knowing before you conclude that a shortage, a switch, or a mistake has occurred. It is also worth knowing before you assume the reverse, since availability differs by country and changes over time, and neither a news article nor this page can tell you what your local pharmacy is currently dispensing.

What this means when you read about the other name

Take a report describing a study, a price, an insurance decision, or a supply problem under one of these names. The ingredient facts in it generally carry across. The product facts often do not: pack presentations, device details, licensed indications, prices, and coverage rules are all attached to a specific product in a specific market, and can differ even between two products containing the same substance.

Dose figures deserve particular care. Numbers quoted under one brand name are not a translation table for the other, and this page publishes none. UK government guidance asks people to consult a healthcare professional before switching from one GLP-1 medicine to another, and says that switching without medical advice may increase the risk of experiencing side effects or make the treatment less effective. The online charts that claim otherwise are precisely what that warning is about.

What to record so the ambiguity never reaches your notes

  • The brand name printed on your carton or dispensing label, copied rather than recalled
  • Tirzepatide as the active ingredient, written out in full
  • The country where the medicine was dispensed, which is the field that explains the brand name later
  • The licensed use your prescriber recorded, in the words they used
  • The date you started, and the date of any change, kept as two separate entries rather than one running line
  • The strength and pack details as printed, transcribed exactly

An accurate personal medication list of this kind is what official consumer guidance recommends anyway, and it is the thing that makes the rest of your tracking legible to someone else months later.

Talking to a clinician who uses the other name

This comes up when you have moved country, are being seen privately after starting elsewhere, or are talking to someone who follows international coverage more closely than local supply. The reliable move is to lead with the ingredient and follow with the product: say tirzepatide, then say which brand name is on your box, then say where it was dispensed. That sequence resolves the ambiguity in one sentence and does not depend on both of you recognising the same brand.

The same sequence works in writing. A message to a clinic that opens with the ingredient, then the brand, then the country of supply, rarely needs a follow-up exchange to establish what you are actually taking, whereas one that opens with a brand name alone frequently does. That is a small saving on any single occasion and a considerable one across a course of treatment measured in years.

Bringing the packaging itself, or a photograph of it, does the same job faster and removes any chance of a transcription error. If you have used more than one product over time, bring the dates too, since the order and duration of what you have taken is usually the part a reviewer most wants and the part a patient most often has to reconstruct on the spot.

What is not on this page

There is no comparison of how well these two products work, no claim that either is easier to tolerate, and no suggestion about which one anyone should be taking. Those are clinical questions, and the answer depends on medical history, other medicines, what treatment is for, and local availability, none of which a general page has access to.

For the possible side effects of these medicines, the regulator material and the leaflet inside your pack are the right sources, and MHRA has reminded both patients and professionals to stay alert to them. If symptoms are severe or getting worse quickly, that is a reason to seek urgent medical help, not a reason to open your tracking app.